摘要
目的观察紫杉醇脂质体联合顺铂在初、复治晚期食管鳞癌患者中的应用效果。方法回顾性分析郑州大学第一附属医院2015年2月至2018年6月收治的99例晚期食管鳞癌患者临床资料。初治组51例,复治组48例。患者均完成紫杉醇脂质体(150 mg·m^-2,第1天)联合顺铂(30 mg·m^-2,第1~2天)至少2个周期的化疗(每3周为1个化疗周期),直至疾病进展或不能耐受。比较两组近期疗效、远期疗效,以及不良反应发生情况。每2个周期评估1次近期疗效,末次随访日期为2019年7月。结果根据实体瘤的疗效评价标准(RECIST)1.1版,初治组和复治组治疗有效率分别为41.2%(21/51)、31.3%(15/48),差异无统计学意义(P>0.05)。初治组和复治组中位总生存期(OS)分别为11.0、10.3个月,中位无进展生存期(PFS)分别为6.0、5.2个月,两组OS、PFS差异无统计学意义(均P>0.05)。复治组中性粒细胞减少和乏力发生率高于初治组(均P<0.05)。结论紫杉醇脂质体联合顺铂对初治与复治晚期食管鳞癌患者的疗效相当,复治患者中性粒细胞减少和乏力发生率高于初治患者。
Objective To compare the effect of paclitaxel liposome combined with cisplatin in patients with incipient and relapsed advanced esophageal squamous cell carcinoma.Methods The clinical data of 99 patients with advanced esophageal squamous cell carcinoma admitted to the First Affiliated Hospital of Zhengzhou University from February 2015 to June 2018 were retrospectively analyzed. There were 51 cases in incipient group and 48 cases in relapsed group. All patients completed at least 2 cycles of chemotherapy with paclitaxel liposomes(150 mg·m^-2, d1) combined with cisplatin(30 mg·m^-2, d1-2) until disease progression or intolerance. Each chemotherapy cycle was 3 weeks. The short-term curative effect, long-term curative effect, and adverse reaction were compared between the two groups. The short-term efficacy was evaluated every 2 cycles, and the last follow-up date was July 2019.Results According to the Response Evaluation Criteria in Solid Tumors(RECIST) 1.1, the response rates in incipient group and relapsed group were 41.2%(21/51) and 31.3%(15/48), respectively, with no statistical difference(P>0.05). The median overall survival(OS) of incipient group and relapsed group was 11.0 and 10.3 months, respectively. The median progression-free survival(PFS) of incipient group and relapsed group was 6.0 and 5.2 months, respectively. There were no statistical differences in OS and PFS between the two groups(both P>0.05). The incidences of neutropenia and fatigue in relapsed group were higher than those in incipient group(both P<0.05).Conclusion The combination of paclitaxel liposomes and cisplatin is equivalent to the incipient and relapsed patients with advanced esophageal squamous cell carcinoma. The incidences of neutropenia and fatigue in relapsed patients are higher than those inincipient patients.
作者
丁鹏
秦艳茹
DING Peng;QIN Yan-ru(Department of Oncology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450000,China)
出处
《河南医学研究》
CAS
2020年第17期3090-3094,共5页
Henan Medical Research
基金
国家自然科学基金(81872264)。
关键词
食管癌
紫杉醇脂质体
顺铂
化疗
esophageal cancer
paclitaxel liposome
cisplatin
chemotherapy
